ISAL 2019 | Inhibitors of IDH1 and IDH2 for targeted therapy in acute myeloid leukemia
Patients with IDH1 or IDH2 mutant R/R AML can be treated with the oral agents, ivosidenib, and enasidenib, which are safe and effective as single-agent therapy.
AML World Awareness Day 2020 | Clinical trials involving novel agents in AML
On April 21, 2020, communities will unite on Acute Myeloid Leukemia (AML) World Awareness Day (WAD) to raise awareness of AML. Both scientific and patient communities will...
Subscribe to get the best content related to AML delivered to your inbox every month